PTK2 and breast cancer: Clinically, circCDYL2 could be used as a new molecule for predicting the prognosis of HER2+ BC patients, and we proved that FAK or GRB7 inhibitor could be used to reverse trastuzumab resistance of HER2+ BC patients (Fig. S4).